phrykt

Inmune Bio, Inc. (INMB): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of INMB were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No INMB insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

INMB short interest

Moderate short interest. 9.6% of INMB shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 27%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.66M INMB shares were sold short, 9.6% of the shares outstanding, down 7.9% from the report before. At the average daily volume of 184,693 shares, buying them all back would take about 14.4 trading days (days to cover).

Shares short, % of all shares

9.58%May 15Oct 3014.8%

Days to cover

14.4May 15Oct 3016.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.66M9.58%-8%184,69314.4
Oct 15, 20262.89M10.40%+9%349,8148.2
Sep 30, 20262.66M9.58%+18%381,6207.0
Sep 15, 20262.25M8.11%+3%289,1777.8
Aug 31, 20262.18M7.87%+4%349,1006.3
Aug 14, 20262.10M7.57%-5%421,8465.0
Jul 31, 20262.20M8.29%-8%331,6256.6
Jul 15, 20262.38M8.97%-22%1.08M2.2
Jun 30, 20263.07M11.54%-16%1.90M1.6
Jun 15, 20263.67M13.80%-1%325,48411.3
May 29, 20263.69M13.88%+1%256,56014.4
May 15, 20263.64M13.70%+3%681,6675.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Inmune Bio company events

Inmune Bio filed 23 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026AgreementINmune Bio Inc. entered into a securities purchase agreement with a single investor, pursuant to which the Company agreed to issue and sell to the Purchaser, in a registered direct offering, 3,000,000 shares of the Company’s common stock, par value $0.001 per share, at an offering price of $1.50… Filing
  2. Oct 21, 2026AnnouncementThe Company issued two press releases related to Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB), announcing that the Company (i) has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited establishing a scalable… Filing
  3. Sep 14, 2026LeadershipThe Board of Directors of INmune Bio, Inc. approved to increase the number of directors and to set the number of directors serving on the Board at seven, and, pursuant to the Company’s by-Laws, appointed R. Duane Clark II and James Sapirstein to serve as directors of the Company until the next… Filing
  4. Jul 31, 2026AnnouncementINmune Bio Inc. issued a press release announcing that on July 30, 2026, it received a research and development cash rebate from Australia of approximately $4.2 million. Filing
  5. Jul 1, 2026AgreementINmune Bio Inc. (the Company”) entered into a warrant inducement offer letter agreement and into an amendment to common stock purchase warrant with certain holders of common stock purchase warrants previously issued by the Company in its April 2024 offerings on April 24, 2024 and April 29, 2024, as… Filing
  6. Jun 23, 2026AnnouncementINmune Bio Inc. issued a press release announcing that it has received official, accepted meeting minutes from its recent face-to-face pre-Marketing Authorization Application (pre-MAA) Scientific Advice meeting with the UK Medicines & Healthcare products Regulatory Agency (MHRA) for CORDStrom™… Filing
  7. Jun 17, 2026LeadershipAs noted in Item 5.07 below, on June 16, 2026, INmune Bio Inc., held its annual meeting of stockholders, where the stockholders of the Company approved the Company’s Third Amended and Restated 2021 Stock Incentive Plan, pursuant to which the shares of the Company’s common stock issuable under the… Filing
  8. Jun 2, 2026AnnouncementINmune Bio Inc. issued a press release announcing results from exploratory chi-separation (χ-separation) MRI imaging analyses from the MINDFuL Phase 2 clinical trial of XPro™ (XPro1595) in patients with early Alzheimer's disease encompassing both mild cognitive impairment (MCI) and mild Alzheimer’s… Filing
  9. May 14, 2026AnnouncementINmune Bio Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XPro™ ( pegipanermin ), the company's first-in-class selective soluble TNF inhibitor, for the treatment of early Alzheimer's disease (AD). Filing
  10. May 5, 2026AgreementINmune Bio Inc. entered into an amended and restated Material Transfer and License Agreement with INmune Bio International, a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan, a company limited by guarantee incorporated in England, which amended and… Filing
  11. Feb 27, 2026AnnouncementShared information with investors. Filing
  12. Feb 23, 2026AnnouncementINmune Bio Inc. issued a press release announcing that the Company will host a webinar on the registrational pathway of XPro1595 for the treatment of early Alzheimer’s disease on February 27, 2026, at 9:30 a.m. Filing
  13. Feb 19, 2026AnnouncementINmune Bio Inc. issued a press release announcing that the Company will host a webinar on CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa on February 26, 2026, at 1:00 p.m. Filing
  14. Feb 13, 2026AnnouncementShared information with investors. Filing
  15. Jan 27, 2026AnnouncementShared information with investors. Filing
  16. Dec 23, 2025AgreementINmune Bio Inc. entered into an amendment with certain holders of warrants previously issued by the Company in its April 2024 offerings on April 24, 2024 and April 29, 2024, respectively. Filing
  17. Dec 19, 2025AgreementINmune Bio Inc. entered into a Sales Agreement with A.G.P./Alliance Global Partners, as sales agent, pursuant to which the Company may offer and sell, from time to time, through A.G.P., up to $65 million of shares of its common stock, par value $0.001 per share. Filing
  18. Dec 10, 2025AgreementEnded an important agreement. Filing
  19. Dec 8, 2025AgreementINmune Bio Inc. entered into Amendment No. 5 to the Rights Agreement, dated as of December 30, 2020, between the Company and VStock Transfer, LLC, as Rights Agent, as amended. Filing
  20. Dec 5, 2025AnnouncementINmune Bio Inc. issued a press release announcing new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer’s disease and elevated neuroinflammation. Filing
  21. Dec 3, 2025LeadershipINmune Bio Inc. and David J. Moss, the Company’s President and Chief Executive entered into an amendment to Mr. Moss’s employment agreement, dated November 26, 2025, to correct a mistake in the original agreement, restating his base salary to $454,000 per annum and restating his option grant under… Filing
  22. Nov 28, 2025LeadershipINmune Bio Inc. and David J. Moss, the Company’s President and Chief Executive entered into an employment agreement. Filing
  23. Nov 18, 2025LeadershipINmune Bio Inc. held a special meeting of stockholders in a virtual meeting format via live webcast. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Inmune Bio financials

Famous investors that hold INMB

3 of the 50 well-known investors we track reported holding INMB in their latest 13F filing. The largest position is Jim Simons's, worth $581K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026298,000$581K0.0%+903%
Ken Griffin · Citadel AdvisorsQ3 2026138,349$270K0.0%+30%
Israel Englander · Millennium ManagementQ3 202699,534$194K0.0%-38%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named INMB in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Highbridge Capital Management, LLC13G/A5.0%
Nov 16, 2026Highbridge Capital Management, LLC13G/A5.0%

Questions about Inmune Bio, Inc. (INMB) stock

Are INMB insiders buying or selling?

No INMB insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in INMB?

As of Oct 30, 2026, 2.66M INMB shares were sold short, 9.6% of the shares outstanding, down 7.9% from the report before. At the average daily volume of 184,693 shares, buying them all back would take about 14.4 trading days (days to cover). See the history.

Which famous investors hold INMB?

3 of the 50 well-known investors we track reported INMB in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $581K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.